These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

581 related articles for article (PubMed ID: 24727139)

  • 1. Unique molecular alteration patterns in von Hippel-Lindau (VHL) gene in a cohort of sporadic renal cell carcinoma patients from Pakistan.
    Khaliq S; Ajaz S; Firasat S; Shahid S; Hasan AS; Sultan G; Mohsin R; Hashmi A; Mubarak M; Naqvi SA; Rizvi SA; Mehdi SQ; Abid A
    Mutat Res; 2014; 763-764():45-52. PubMed ID: 24727139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma.
    Morrissey C; Martinez A; Zatyka M; Agathanggelou A; Honorio S; Astuti D; Morgan NV; Moch H; Richards FM; Kishida T; Yao M; Schraml P; Latif F; Maher ER
    Cancer Res; 2001 Oct; 61(19):7277-81. PubMed ID: 11585766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis.
    Clifford SC; Prowse AH; Affara NA; Buys CH; Maher ER
    Genes Chromosomes Cancer; 1998 Jul; 22(3):200-9. PubMed ID: 9624531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Somatic VHL alteration and its impact on prognosis in patients with clear cell renal cell carcinoma.
    Kim JH; Jung CW; Cho YH; Lee J; Lee SH; Kim HY; Park J; Park JO; Kim K; Kim WS; Park YS; Im YH; Kang WK; Park K
    Oncol Rep; 2005 May; 13(5):859-64. PubMed ID: 15809750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. VHL alterations in human clear cell renal cell carcinoma: association with advanced tumor stage and a novel hot spot mutation.
    Brauch H; Weirich G; Brieger J; Glavac D; Rödl H; Eichinger M; Feurer M; Weidt E; Puranakanitstha C; Neuhaus C; Pomer S; Brenner W; Schirmacher P; Störkel S; Rotter M; Masera A; Gugeler N; Decker HJ
    Cancer Res; 2000 Apr; 60(7):1942-8. PubMed ID: 10766184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: relationship to clinicopathological parameters.
    Kondo K; Yao M; Yoshida M; Kishida T; Shuin T; Miura T; Moriyama M; Kobayashi K; Sakai N; Kaneko S; Kawakami S; Baba M; Nakaigawa N; Nagashima Y; Nakatani Y; Hosaka M
    Genes Chromosomes Cancer; 2002 May; 34(1):58-68. PubMed ID: 11921283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic and epigenetic alterations in the von hippel-lindau gene: the influence on renal cancer prognosis.
    Smits KM; Schouten LJ; van Dijk BA; Hulsbergen-van de Kaa CA; Wouters KA; Oosterwijk E; van Engeland M; van den Brandt PA
    Clin Cancer Res; 2008 Feb; 14(3):782-7. PubMed ID: 18245539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Somatic mutations of the von Hippel-Lindau disease gene in renal carcinomas occurring in patients with long-term dialysis.
    Inoue H; Nonomura N; Kojima Y; Shiba M; Oka D; Arai Y; Nakayama M; Takayama H; Nishimura K; Mori H; Okuyama A
    Nephrol Dial Transplant; 2007 Jul; 22(7):2052-5. PubMed ID: 17438007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinicopathologic and molecular genetic study of renal cell carcinoma occurring in teenagers].
    Rao Q; Zhou J; Zhang RS; Ma HH; Zhou HB; Lu ZF; Zhou XJ
    Zhonghua Bing Li Xue Za Zhi; 2010 Sep; 39(9):582-6. PubMed ID: 21092583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel mutations of the von hippel-lindau tumor-suppressor gene and rare DNA hypermethylation in renal-cell carcinoma cell lines of the clear-cell type.
    Meyer AJ; Hernandez A; Florl AR; Enczmann J; Gerharz CD; Schulz WA; Wernet P; Ackermann R
    Int J Cancer; 2000 Sep; 87(5):650-3. PubMed ID: 10925357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alcohol consumption and mutations or promoter hypermethylation of the von Hippel-Lindau gene in renal cell carcinoma.
    Schouten LJ; van Dijk BA; Oosterwijk E; van Engeland M; Hulsbergen-van de Kaa CA; Kiemeney LA; Goldbohm RA; Kester A; de Vogel S; Schalken JA; van den Brandt PA
    Cancer Epidemiol Biomarkers Prev; 2008 Dec; 17(12):3543-50. PubMed ID: 19064569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomic organization and chromosomal localization of the human CUL2 gene and the role of von Hippel-Lindau tumor suppressor-binding protein (CUL2 and VBP1) mutation and loss in renal-cell carcinoma development.
    Clifford SC; Walsh S; Hewson K; Green EK; Brinke A; Green PM; Gianelli F; Eng C; Maher ER
    Genes Chromosomes Cancer; 1999 Sep; 26(1):20-8. PubMed ID: 10441001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer.
    Banks RE; Tirukonda P; Taylor C; Hornigold N; Astuti D; Cohen D; Maher ER; Stanley AJ; Harnden P; Joyce A; Knowles M; Selby PJ
    Cancer Res; 2006 Feb; 66(4):2000-11. PubMed ID: 16488999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Clinicopathological Significance of Epigenetic Silencing of VHL Promoter and Renal Cell Carcinoma: A Meta-Analysis.
    Yang L; Zhao Z; Zhao S; Chen C; Cong X; Li Z; Ren M
    Cell Physiol Biochem; 2016; 40(6):1465-1472. PubMed ID: 27997886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. von Hippel-Lindau exonic methylation analysis using MALDI-TOF mass spectrometry.
    Lian F; Sreedharan S; Arnold RS; Master VA; Ogan K; Pattaras JG; Roberts DL; Petros JA
    J Urol; 2014 Nov; 192(5):1528-33. PubMed ID: 24704013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Von Hippel-Lindau (VHL) inactivation in sporadic clear cell renal cancer: associations with germline VHL polymorphisms and etiologic risk factors.
    Moore LE; Nickerson ML; Brennan P; Toro JR; Jaeger E; Rinsky J; Han SS; Zaridze D; Matveev V; Janout V; Kollarova H; Bencko V; Navratilova M; Szeszenia-Dabrowska N; Mates D; Schmidt LS; Lenz P; Karami S; Linehan WM; Merino M; Chanock S; Boffetta P; Chow WH; Waldman FM; Rothman N
    PLoS Genet; 2011 Oct; 7(10):e1002312. PubMed ID: 22022277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors.
    Nickerson ML; Jaeger E; Shi Y; Durocher JA; Mahurkar S; Zaridze D; Matveev V; Janout V; Kollarova H; Bencko V; Navratilova M; Szeszenia-Dabrowska N; Mates D; Mukeria A; Holcatova I; Schmidt LS; Toro JR; Karami S; Hung R; Gerard GF; Linehan WM; Merino M; Zbar B; Boffetta P; Brennan P; Rothman N; Chow WH; Waldman FM; Moore LE
    Clin Cancer Res; 2008 Aug; 14(15):4726-34. PubMed ID: 18676741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Somatic von Hippel-Lindau disease gene mutation in clear-cell renal carcinomas associated with end-stage renal disease/acquired cystic disease of the kidney.
    Yoshida M; Yao M; Ishikawa I; Kishida T; Nagashima Y; Kondo K; Nakaigawa N; Hosaka M
    Genes Chromosomes Cancer; 2002 Dec; 35(4):359-64. PubMed ID: 12378530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of circulating cancer cells with von hippel-lindau gene mutation in peripheral blood of patients with renal cell carcinoma.
    Ashida S; Okuda H; Chikazawa M; Tanimura M; Sugita O; Yamamoto Y; Nakamura S; Moriyama M; Shuin T
    Clin Cancer Res; 2000 Oct; 6(10):3817-22. PubMed ID: 11051223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of E2F1 by the von Hippel-Lindau tumour suppressor protein predicts survival in renal cell cancer patients.
    Mans DA; Vermaat JS; Weijts BG; van Rooijen E; van Reeuwijk J; Boldt K; Daenen LG; van der Groep P; Rowland BD; Jans JJ; Roepman R; Voest EE; van Diest PJ; Verhaar MC; de Bruin A; Giles RH
    J Pathol; 2013 Sep; 231(1):117-29. PubMed ID: 23744542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.